Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

BOLD

Boundless Bio Inc.

May 17 • 04:00PM ET

9.67

Dollar change -0.29
Percentage change -2.91	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	36.54%	Shs Outstand	22.24M	Perf Week	12.57%
Market Cap	215.16M	Forward P/E	-	EPS next Y	-4.59	Insider Trans	9.70%	Shs Float	14.12M	Perf Month	-14.42%
Income	-	PEG	-	EPS next Q	-0.80	Inst Own	53.66%	Short Float	6.02%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	90.18%	Inst Trans	-	Short Ratio	4.16	Perf Half Y	-
Book/sh	-111.82	P/B	-	EPS next Y	-15.16%	ROA	-	Short Interest	0.85M	Perf Year	-
Cash/sh	4.71	P/C	2.05	EPS next 5Y	-	ROE	-	52W Range	8.51 - 15.24	Perf YTD	-32.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-36.55%	Beta	-
Dividend TTM	-	Quick Ratio	10.54	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.63%	ATR (14)	1.02
Dividend Ex-Date	-	Current Ratio	10.54	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	41.27	Volatility	10.33% 11.71%
Employees	72	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	23.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-2207.48%	Payout	-	Rel Volume	0.45	Prev Close	9.96
Sales Surprise	-	EPS Surprise	-1817.19%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	204.39K	Price	9.67
SMA20	-3.76%	SMA50	-12.14%	SMA200	-12.14%	Trades		Volume	92,480	Change	-2.91%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
08:00AM	Loading…
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 02 '24	Buy	16.00	312,500	5,000,000	1,884,787	Apr 04 04:15 PM
ARCH Venture Fund IX, L.P.	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
CRANDELL KEITH	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
Burow Kristina	Director	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM

BOLD

Boundless Bio Inc.

Upgrade your FINVIZ experience